12:21 PM
 | 
Dec 19, 2018
 |  BC Extra  |  Company News

Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor antigen-targeted therapies.

On Wednesday, Amgen received exclusive, worldwide rights to develop and commercialize tumor stroma-targeted MP0310 from Molecular Partners for $50 million up front and up to $497 million...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >